Can a nasal spray of stem cell 'Messages' slow Alzheimer's?

NCT ID NCT07457125

First seen Mar 11, 2026 · Last updated Jun 19, 2026 · Updated 20 times

Summary

This early-stage trial is testing whether a nasal spray containing exosomes from umbilical cord stem cells is safe and might help people with mild to moderate Alzheimer's. The study involves 33 participants and will first test different doses, then compare the best dose to a placebo. The main focus is on safety, but researchers will also check if it affects memory and thinking.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD TO MODERATE ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Xuanwu Hospital, Capital Medical University

    RECRUITING

    Beijing, 100053, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

exosomes derived from umbilical cord mesenchymal stem cells (CB-Exo-A600) given as a nasal spray

What this could lead to

If it works, this could point toward a new way to slow or manage Alzheimer's symptoms using stem cell-derived exosomes delivered through the nose.

What could go wrong

This is an early Phase 1/2 trial with only 33 participants, so it is too small to prove effectiveness. The main goal is safety, and it is unknown if the treatment will actually help memory or thinking.

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.